belantamab

Belantamab (GSK2857914) is a humanized, afucosylated IgG1 monoclonal antibody directed against B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. Developed by GSK, belantamab is the "naked" antibody version of the antibody-drug conjugate (ADC) belantamab mafodotin (Blenrep). Unlike the ADC, belantamab does not contain a cytotoxic payload and is designed to exert anti-tumor activity primarily through immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The afucosylation of the antibody's Fc region, achieved via POTELLIGENT technology, enhances its affinity for FcγRIIIa receptors on effector cells, thereby boosting ADCC. By omitting the monomethyl auristatin F (MMAF) payload, belantamab aims to provide clinical anti-myeloma activity while avoiding the corneal toxicities (keratopathy) typically associated with the ADC version. It is currently being evaluated in clinical trials, such as the DREAMM-20 study, for patients with relapsed or refractory multiple myeloma.

Other names

倍赛诺他GSK-2857914GSK2857914GSK 2857914